In MET-amplified NSCLC, heterodimers of MET with EGFR, HER2, and HER3 activate the AKT and ERK signaling pathways, thereby enhancing lung cancer cell proliferation and survival. Here, EGFR is linked to non-small cell lung carcinoma.